HER2-low Unresectable and/or Metastatic Breast Cancer in Russia

A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

NCT07281001 ·Status: RECRUITING ·Phase: NA

Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer

NCT00770354 ·Status: TERMINATED ·Phase: PHASE2

A Study To Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

NCT02616224 ·Status: WITHDRAWN

HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council

NCT06125314 ·Status: COMPLETED

Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis

NCT02560311 ·Status: UNKNOWN

Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer

NCT04857619 ·Status: COMPLETED

The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

NCT04753177 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Observational Study on the Treatment of Patients With Metastatic Breast Cancer

NCT06676436 ·Status: COMPLETED

Safety of Herceptin/Trastuzumab in Metastatic Breast Cancer

NCT02424682 ·Status: COMPLETED

Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer

NCT01548677 ·Status: COMPLETED ·Phase: PHASE2

Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer

NCT05959291 ·Status: RECRUITING ·Phase: NA

Association Between HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving Neoadjuvant Endocrine or Chemotherapy

NCT05673850 ·Status: COMPLETED

A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer

NCT02748213 ·Status: COMPLETED ·Phase: PHASE2

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

NCT07179939 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy

NCT04578106 ·Status: TERMINATED ·Phase: PHASE2

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

NCT06040593 ·Status: COMPLETED

Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer

NCT06299852 ·Status: RECRUITING ·Phase: NA

Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer

NCT01428414 ·Status: UNKNOWN ·Phase: PHASE2

Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients

NCT01420146 ·Status: COMPLETED ·Phase: PHASE1

Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer

NCT04337658 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC

NCT00134680 ·Status: COMPLETED ·Phase: PHASE2

Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin

NCT05004142 ·Status: UNKNOWN ·Phase: PHASE2

Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

NCT06344793 ·Status: COMPLETED

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

NCT00038402 ·Status: COMPLETED ·Phase: PHASE3

Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer

NCT03497702 ·Status: UNKNOWN ·Phase: PHASE2